Idera Pharmaceuticals Inc (IDRA)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

505 EAGLEVIEW BOULEVARD EXTON, PA 19341

Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.

Data as of 2021-07-19 08:35:39 -0400
Market Cap52.035 Million Shares Outstanding50.033 Million Avg 30-day Volume5.99 Million
P/E Ratio-0.59648 Dividend Yield EPS-2.67
Price/Sales-105.12 Debt to Equity-1.0 EBITDA-40.848 Million
Price to Book Value-1.6 Forward PE-0.01 Enterprise Value23.056 Million
Total Cash28.979 Million Current Debt6.805 Million Gross Profit-495 Thousand
BETA0.95541 52-week High/Low6.14 / 0.971 Next Earnings Date2021-08-03 Price to Cash FLow (P/CF) 0.4382
Data provided by IEX Cloud
View SEC Filings from IDRA instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 1 1 0.0% 0 (0.0%) 0 (0.0%)
Funds Holding: 57 55 3.64% 17 (1.0%) 17 (0.99%) 0.0%
13F shares: 9.83 Million 9.538 Million 3.06% 6.072 Million 6.794 Million -10.64%
% Ownership 23.2631 27.0043 -13.85% 14.3683 19.2364 -25.31%
New Positions: 17 15 13.33% 3 5 -40.0%
Increased Positions 20 15 33.33% 8 6 33.33%
Closed Positions 14 2 600.0% 3
Reduced Positions 11 11 0.0% 3 1 200.0%
Total Calls 517.548 Thousand 67.222 Thousand 669.91% 298.9 Thousand 41.2 Thousand 625.49%
Total Puts 1.385 Million 46.909 Thousand 2853.35% 521.3 Thousand
PUT/CALL Ratio 2.68 0.7 282.86% 1.74 0.0
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding IDRA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IDRA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

135 Thousand total shares from 2 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MILANO VINCENT PRESIDENT AND CEO

124,000 2021-07-08 4

LIM BRYANT DAVID SVP AND GENERAL COUNSEL

66,500 2021-07-08 4

KIRBY JOHN J. CHIEF FINANCIAL OFFICER

66,500 2021-07-08 4

SOLAND DANIEL B CHIEF OPERATING OFFICER

66,500 2021-07-08 5

GERAGHTY JAMES A

26,000 2021-06-08 4

GOLDBERG MARK ALAN

26,000 2021-06-08 4

GOWEN MAXINE

26,000 2021-06-08 1

SCHAFER CAROL

26,000 2021-06-08 4

DOUGHERTY MICHAEL R

26,000 2021-06-08 5

CSIMMA CRISTINA

26,000 2021-06-08 1

PILLAR INVEST CORP

PILLAR PARTNERS FOUNDATION, L.P.

PILLAR PHARMACEUTICALS 6, L.P.

UMARI ABUDE

ZEIN YOUSSEF EL

  • 10% Owner
10,946,202 2021-04-01 3

TARKA ELIZABETH ANN CHIEF MEDICAL OFFICER

13,237 2021-03-25 2

PIEN HOWARD H

  • Director
45,457 2020-10-01 1

FLETCHER ROBERT C. SR. VP, BUS. DEV. & STRATEGY

  • Officer
0 2020-07-21 0

PILLAR INVEST CORP

PILLAR PARTNERS FOUNDATION, L.P.

UMARI ABUDE

ZEIN YOUSSEF EL

  • 10% Owner
7,010,824 2020-07-13 3

PILLAR INVEST CORP

PILLAR PHARMACEUTICALS I LP

PILLAR PHARMACEUTICALS II, L.P.

PILLAR PHARMACEUTICALS III, L.P.

PILLAR PHARMACEUTICALS IV, L.P.

PILLAR PHARMACEUTICALS V LP

PILLAR PHARMACEUTICALS 6, L.P.

PILLAR PARTNERS FOUNDATION, L.P.

UMARI ABUDE

ZEIN YOUSSEF EL

  • 10% Owner
No longer subject to file 2020-01-27 0

YINGLING JONATHAN MICHAEL CHIEF SCIENTIFIC OFFICER

  • Officer
36,358 2020-01-10 0

HOROBIN JOANNA CHIEF MEDICAL OFFICER

  • Officer
0 2019-07-09 0

BAKER BROS. ADVISORS LP

BAKER BROS. ADVISORS (GP) LLC

BAKER FELIX

BAKER JULIAN

  • 10% Owner
4,685,574 2019-07-01 0

BAKER BROS. ADVISORS LP

14159, L.P.

667, L.P.

BAKER BROS. ADVISORS (GP) LLC

BAKER BROTHERS LIFE SCIENCES LP

BAKER FELIX

BAKER JULIAN

  • Director
  • 10% Owner
4,903,988 2019-04-01 0

ARCUDI III LOUIS J CHIEF FINANCIAL OFFICER

  • Officer
0 2018-08-13 0

PILLAR INVEST CORP

PILLAR PHARMACEUTICALS I LP

PILLAR PHARMACEUTICALS II, L.P.

PILLAR PHARMACEUTICALS III, L.P.

  • 10% Owner
No longer subject to file 2018-08-07 3

PILLAR INVEST CORP

PILLAR PHARMACEUTICALS II, L.P.

  • 10% Owner
0 2018-07-18 3

REARDON WILLIAM S

  • Director
0 2018-06-20 0

PILLAR INVEST CORP

  • 10% Owner
0 2018-04-25 3

PILLAR INVEST CORP

PILLAR PHARMACEUTICALS III, L.P.

  • 10% Owner
0 2018-01-17 0

CASEY MARK J SENIOR VP & GENERAL COUNSEL

  • Officer
0 2018-01-03 0

PILLAR INVEST CORP

PILLAR PHARMACEUTICALS II, L.P.

PILLAR PHARMACEUTICALS III, L.P.

  • 10% Owner
0 2017-12-13 0

PILLAR INVEST CORP

PILLAR PHARMACEUTICALS II, L.P.

ZEIN YOUSSEF EL

  • Director
  • 10% Owner
0 2017-10-16 0

ZEIN YOUSSEF EL

  • Director
  • 10% Owner
539,410 2017-10-02 0

PILLAR INVEST CORP

PILLAR PHARMACEUTICALS I LP

PILLAR PHARMACEUTICALS II, L.P.

ZEIN YOUSSEF EL

  • Director
  • 10% Owner
0 2017-05-01 0

PILLAR INVEST CORP

PILLAR PHARMACEUTICALS I LP

ZEIN YOUSSEF EL

  • Director
  • 10% Owner
0 2017-04-24 0

AGRAWAL SUDHIR PRESIDENT OF RESEARCH

  • Officer
  • Director
0 2017-01-03 0

PILLAR PHARMACEUTICALS V LP

  • Director
  • 10% Owner
875,000 2016-10-07 0

PILLAR INVEST CORP

PILLAR PHARMACEUTICALS I LP

PILLAR PHARMACEUTICALS II, L.P.

PILLAR PHARMACEUTICALS III, L.P.

PILLAR PHARMACEUTICALS IV, L.P.

ZEIN YOUSSEF EL

  • Director
  • 10% Owner
0 2015-12-15 0

SLATER EVE ELIZABETH

  • Director
0 2015-06-08 0

BRENNER LOUIS MD CHIEF MEDICAL OFFICER

  • Officer
0 2014-12-10 0

WOLF JOHN PETER III GENERAL COUNSEL

  • Officer
0 2014-12-10 0

MACCOSS MALCOLM

  • Director
3,753 2014-07-01 0

KARR ROBERT W

  • Director
0 2014-06-09 0

SULLIVAN TIMOTHY M VP DEVELOPMENT PROGRAMS

  • Officer
24,914 2014-05-27 0

ABDUL-WAHAB UMARI

  • Director
0 2014-05-21 0

NEU KELVIN

  • Director
0 2014-03-10 0

ARBEIT ROBERT D. VP CLINICAL DEVELOPMENT

  • Officer
0 2013-12-10 0

PILLAR PHARMACEUTICALS IV, L.P.

  • Director
  • 10% Owner
845,161 2013-09-30 0

PILLAR INVEST CORP

PILLAR PHARMACEUTICALS IV, L.P.

ZEIN YOUSSEF EL

  • Director
  • 10% Owner
0 2013-09-30 0

HARTLEY C KEITH

  • Director
0 2013-08-16 0

PILLAR PHARMACEUTICALS III, L.P.

  • Director
  • 10% Owner
2,600,000 2013-05-07 0

PILLAR INVEST CORP

ZEIN YOUSSEF EL

  • Director
  • 10% Owner
0 2012-11-09 0

PILLAR PHARMACEUTICALS II, L.P.

  • Director
  • 10% Owner
0 2012-11-09 0

SENATOR INVESTMENT GROUP LP

  • 10% Owner
No longer subject to file 2012-04-19 0

PILLAR PHARMACEUTICALS I LP

PILLAR INVEST CORP

  • Director
  • 10% Owner
0 2011-11-04 0

WYNGAARDEN JAMES B

  • Director
0 2011-06-14 0

MUELLER HANS

  • Director
0 2011-06-14 0

BEXON ALICE V.P. CLINICAL DEVELOPMENT

  • Officer
0 2009-12-23 0

ALISON TAUNTON-RIGBY

  • Director
0 2009-06-16 0

BAKER BROTHERS LIFE SCIENCES CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
418,030 2008-07-28 0

14159 CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
12,867 2008-07-28 0

BAKER BIOTECH CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
209,110 2008-07-28 0

BAKER BROS. CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
40,077 2008-07-28 0

ZAMECNIK PAUL C

  • DIRECTOR EMERITUS
104,622 2008-01-02 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

KIRBY JOHN J. CHIEF FINANCIAL OFFICER

2021-07-12 16:05:17 -0400 2021-07-08 A 66,500 a 66,500 direct

MILANO VINCENT PRESIDENT AND CEO

2021-07-12 16:05:37 -0400 2021-07-08 A 124,000 a 124,000 direct

LIM BRYANT DAVID SVP AND GENERAL COUNSEL

2021-07-12 16:05:21 -0400 2021-07-08 A 66,500 a 66,500 direct

SOLAND DANIEL B CHIEF OPERATING OFFICER

2021-07-12 16:05:28 -0400 2021-07-08 A 66,500 a 66,500 direct

SOLAND DANIEL B CHIEF OPERATING OFFICER

2021-06-21 16:10:31 -0400 2021-06-18 P 50,000 $1.19 a 78,843 direct -12.6582 -21.519 0.0 1 -21.519 6

SCHAFER CAROL

2021-06-10 17:05:28 -0400 2021-06-08 A 26,000 a 26,000 direct

GOLDBERG MARK ALAN

2021-06-10 17:06:02 -0400 2021-06-08 A 26,000 a 26,000 direct

CSIMMA CRISTINA

2021-06-10 17:05:43 -0400 2021-06-08 A 26,000 a 26,000 direct

DOUGHERTY MICHAEL R

2021-06-10 17:06:08 -0400 2021-06-08 A 26,000 a 26,000 direct

GOWEN MAXINE

2021-06-10 17:25:21 -0400 2021-06-08 A 26,000 a 26,000 direct

GERAGHTY JAMES A

2021-06-10 17:05:48 -0400 2021-06-08 A 26,000 a 26,000 direct

DOUGHERTY MICHAEL R

2021-06-03 16:10:49 -0400 2021-06-01 P 85,000 $1.19 a 133,584 direct -0.7634 0.0 -21.374 20.6107 13 -22.9008 29

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 22:15:03 UTC -1.4816 1.5616 700000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 21:45:03 UTC -1.4816 1.5616 700000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 21:15:03 UTC -1.4816 1.5616 700000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 20:45:03 UTC -1.4816 1.5616 700000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 20:15:05 UTC -1.4816 1.5616 700000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 19:45:03 UTC -1.4816 1.5616 700000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 19:15:03 UTC -1.4816 1.5616 700000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 18:45:03 UTC -1.4816 1.5616 700000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 18:15:03 UTC -1.4816 1.5616 700000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 17:45:03 UTC -1.4816 1.5616 700000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 17:15:02 UTC -1.4816 1.5616 700000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 16:45:02 UTC -1.4816 1.5616 700000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 16:15:03 UTC -1.4816 1.5616 700000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 15:45:02 UTC -1.4816 1.5616 700000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 15:15:03 UTC -1.4816 1.5616 750000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 14:45:03 UTC -1.4816 1.5616 750000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 14:15:03 UTC -1.4816 1.5616 750000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 13:45:03 UTC -1.4816 1.5616 750000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 13:15:03 UTC -1.4816 1.5616 750000
IDERA PHARMACEUTICALS INC IDRA 2021-07-23 12:45:03 UTC -1.4816 1.5616 700000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments